Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

March 01, 2024

The expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.

February 27, 2024

Rona Yaeger, MD, discusses the implications of data with second-line sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

February 26, 2024

Experts share tips for treating patients with VOD with defibrotide, including strategies to ensure best possible outcomes.

February 23, 2024

A cream formulation of ruxolitinib was deemed safe and effective compared with placebo in patients with cutaneous graft-versus-host disease.

February 23, 2024

The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.

February 23, 2024

A panel of medical oncologists who specialize in renal cell carcinoma (RCC) introduce themselves and discuss the first-line treatment landscape and risk stratification of clear cell RCC.

February 23, 2024

Speculation on anticipated innovations in allo-HSCT and cellular therapy technologies in the future.

February 23, 2024

The expert panel shares emerging data on an engineered, allogeneic cell-based therapy administered as part of conditioning for allo-HSCT in patients with relapsed, refractory, or high-risk hematologic cancers.

February 22, 2024

Liso-cel may be an effective treatment option for patients with relapsed/refractory mantle cell lymphoma and high-risk features.

February 19, 2024

The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.

February 19, 2024

Mitchell Cairo, MD, shares his standard-of-care approach to treating VOD and the role of defibrotide, the only FDA-approved drug for VOD.

February 19, 2024

A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.

February 19, 2024

Sergio Giralt, MD, leads a discussion on the importance of a multidisciplinary team approach in caring for patients with VOD, from recognizing early signs to treating and monitoring the disease.

February 16, 2024

Criteria for identifying patients with MDS most likely to benefit from transplant and choosing the optimal donor source and conditioning regimen on a case-by-case basis.

February 16, 2024

Safety and toxicity data from a clinical trial investigating a novel, precision-engineered allo-HSCT conditioning regimen for older patients with high-risk blood cancers.

February 12, 2024

Mitchell Cairo, MD, and Sergio Giralt, MD, provide insights about the challenges in diagnosing VOD and the need to educate physicians about risk factors for VOD, its pathophysiology, and the importance of early detection.

February 12, 2024

A review of the diagnostic criteria for veno-occlusive disease for pediatric and adult patients.

February 12, 2024

Experts discuss the risk factors associated with VOD and which high-risk patients should be monitored for signs and symptoms of this disease.

February 12, 2024

Mitchell Cairo, MD, and Sergio Giralt, MD, offer an overview of veno-occlusive disease, an endothelial damage syndrome, and its prognosis.

February 12, 2024

The expert panel discusses recent clinical trial data on GPRC5D-targeting bispecific antibodies and how they apply to the multiple myeloma treatment paradigms.